# Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

> **NCT00755534** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 68 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Capecitabine
- **DRUG:** Cetuximab
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00755534
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2013-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755534, "Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00755534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*